{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:34:35Z","timestamp":1772120075253,"version":"3.50.1"},"reference-count":182,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Anaesthesia Critical Care & Pain Medicine"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.accpm.2025.101584","type":"journal-article","created":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T20:01:01Z","timestamp":1750968061000},"page":"101584","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Anticoagulant management in Emergency settings: 2024 guidelines from the French Society of Emergency Medicine (SFMU), the French Society of Anaesthesia and Intensive Care Medicine (SFAR), the French Society of Thrombosis and Haemostasis (SFTH) and the French Working Group on Perioperative Haemostasis (GIHP), endorsed by the French Neurovascular Society"],"prefix":"10.1016","volume":"44","author":[{"given":"Delphine","family":"Douillet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre","family":"Godon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geoffroy","family":"Rousseau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phanie","family":"Ruiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fanny","family":"Vardon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"De Maistre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delphine","family":"Garrigue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Gouin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yves","family":"Gruel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Lanoisel\u00e9e","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Lapostolle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Lasne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-C\u00e9line","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mika\u00ebl","family":"Mazighi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Mismetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Moumneh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Far\u00e8s","family":"Moustafa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Penaloza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phanie","family":"Roullet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre-Marie","family":"Roy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginie","family":"Siguret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeannot","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Tacquard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karim","family":"Tazarourte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Zufferey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Godier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.accpm.2025.101584_bib0005","doi-asserted-by":"crossref","first-page":"e44S","DOI":"10.1378\/chest.11-2292","article-title":"Oral anticoagulant therapy","volume":"141","author":"Ageno","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.accpm.2025.101584_bib0010","doi-asserted-by":"crossref","first-page":"e24S","DOI":"10.1378\/chest.11-2291","article-title":"Parenteral anticoagulants","volume":"141","author":"Garcia","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.accpm.2025.101584_bib0015","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1111\/jth.15901","article-title":"Coagulation assays and direct oral anticoagulant levels among patients having an elective surgery or procedure","volume":"20","author":"Shaw","year":"2022","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.accpm.2025.101584_bib0020","doi-asserted-by":"crossref","first-page":"126","DOI":"10.5853\/jos.2022.03034","article-title":"Practical Nomogram Predicting Apixaban or Rivaroxaban Concentrations from Low-Molecular-Weight Heparin Anti-Xa Values: Special Interest in Acute Ischemic Stroke Patients","volume":"25","author":"Brakta","year":"2023","journal-title":"J Stroke"},{"key":"10.1016\/j.accpm.2025.101584_bib0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.thromres.2022.05.005","article-title":"Low molecular weight heparin anti-Xa assays can identify patients with clinically important apixaban and rivaroxaban drug levels","volume":"215","author":"Mithoowani","year":"2022","journal-title":"Thromb Res"},{"key":"10.1016\/j.accpm.2025.101584_bib0030","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13054-017-1619-z","article-title":"Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants","volume":"21","author":"Ebner","year":"2017","journal-title":"Crit Care"},{"key":"10.1016\/j.accpm.2025.101584_bib0035","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.991675","article-title":"The impact of direct oral anticoagulants on viscoelastic testing \u2013 A systematic review","volume":"9","author":"Sahli","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.accpm.2025.101584_bib0040","unstructured":"Prise en charge des surdosages, des situations \u00e0 risque h\u00e9morragique et des accidents h\u00e9morragiques chez les patients trait\u00e9s par antivitamines K en ville et en milieu hospitalier. Haute Aut Sant\u00e9 n.d. https:\/\/www.has-sante.fr\/jcms\/c_682188\/fr\/prise-en-charge-des-surdosages-des-situations-a-risque-hemorragique-et-des-accidents-hemorragiques-chez-les-patients-traites-par-antivitamines-k-en-ville-et-en-milieu-hospitalier (Accessed 25 June 2025)."},{"key":"10.1016\/j.accpm.2025.101584_bib0045","first-page":"391","article-title":"Management of bleeding and emergency invasive procedures in patients on dabigatran: Updated guidelines from the French Working Group on Perioperative Haemostasis (GIHP) - September 2016","volume":"37","author":"Albaladejo","year":"2018","journal-title":"Anaesth Crit Care Pain Med"},{"key":"10.1016\/j.accpm.2025.101584_bib0050","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1161\/CIRCULATIONAHA.118.036710","article-title":"Idarucizumab for dabigatran reversal in the management of patients with gastrointestinal bleeding","volume":"139","author":"Van der Wall","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.accpm.2025.101584_bib0055","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1182\/blood-2014-03-563577","article-title":"Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry","volume":"124","author":"Beyer-Westendorf","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.accpm.2025.101584_bib0060","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.amjmed.2015.11.030","article-title":"Diagnostic and Therapeutic Yield of Endoscopy in Patients with Elevated INR and Gastrointestinal Bleeding","volume":"129","author":"Peloquin","year":"2016","journal-title":"Am J Med"},{"key":"10.1016\/j.accpm.2025.101584_bib0065","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.thromres.2020.11.011","article-title":"Correction of international normalised ratio in major bleeding related to vitamin K antagonists is associated with better survival: a UK study","volume":"197","author":"Tan","year":"2021","journal-title":"Thromb Res"},{"key":"10.1016\/j.accpm.2025.101584_bib0070","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1056\/NEJMoa1814051","article-title":"Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors","volume":"380","author":"Connolly","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.accpm.2025.101584_bib0075","doi-asserted-by":"crossref","first-page":"e118","DOI":"10.1515\/cclm-2016-0670","article-title":"A 2-min at 4500 g rather than a 15-min at 2200 g centrifugation does not impact the reliability of 10 critical coagulation assays","volume":"55","author":"Boissier","year":"2017","journal-title":"Clin Chem Lab Med CCLM"},{"key":"10.1016\/j.accpm.2025.101584_bib0080","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1055\/a-1400-6159","article-title":"Restart of Anticoagulant Therapy and Risk of Thrombosis, Rebleeding, and Death after Factor Xa Inhibitor Reversal in Major Bleeding Patients","volume":"121","author":"Milling","year":"2021","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.accpm.2025.101584_bib0085","unstructured":"Prise en charge d\u2019une \u00e9pistaxis de l\u2019adulte. ORL Fr 2016. https:\/\/www.orlfrance.org\/recommandation-sforl-prise-en-charge-dune-epistaxis-de-ladulte\/ (Accessed 25 June 2025)."},{"key":"10.1016\/j.accpm.2025.101584_bib0090","unstructured":"Soci\u00e9t\u00e9 francaise de chirurgie orale. Recommandations prise en charge d\u2019un patient sous AVK n\u00e9cessitant une chirurgie orale. n.d."},{"key":"10.1016\/j.accpm.2025.101584_bib0095","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1182\/blood-2017-07-797423","article-title":"How I treat heavy menstrual bleeding associated with anticoagulants","volume":"130","author":"Boonyawat","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.accpm.2025.101584_bib0100","doi-asserted-by":"crossref","first-page":"R81","DOI":"10.1186\/cc13843","article-title":"Guideline-concordant administration of prothrombin complex concentrate and vitamin K is associated with decreased mortality in patients with severe bleeding under vitamin K antagonist treatment (EPAHK study)","volume":"18","author":"Tazarourte","year":"2014","journal-title":"Crit Care Lond Engl"},{"key":"10.1016\/j.accpm.2025.101584_bib0105","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12546","article-title":"Tranexamic acid evidence And controversies: an illustrated review","volume":"5","author":"Relke","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.accpm.2025.101584_bib0110","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13054-019-2347-3","article-title":"The European guideline on management of major bleeding and coagulopathy following trauma: fifth edition","volume":"23","author":"Spahn","year":"2019","journal-title":"Crit Care"},{"key":"10.1016\/j.accpm.2025.101584_bib0115","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1136\/emermed-2012-201976","article-title":"The acute management of haemorrhage, surgery and overdose in patients receiving dabigatran","volume":"31","author":"Alikhan","year":"2014","journal-title":"Emerg Med J"},{"key":"10.1016\/j.accpm.2025.101584_bib0120","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1111\/imj.15786","article-title":"Real\u2010world decision\u2010making in the management of patients presenting with major bleeding on rivaroxaban: the Auckland regional experience","volume":"53","author":"Grainger","year":"2023","journal-title":"Intern Med J"},{"key":"10.1016\/j.accpm.2025.101584_bib0125","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/S0140-6736(20)30848-5","article-title":"Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial","volume":"395","author":"Roberts","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.accpm.2025.101584_bib0130","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1161\/STROKEAHA.123.042866","article-title":"Tranexamic Acid for Intracerebral Hemorrhage in Patients on Non-Vitamin K Antagonist Oral Anticoagulants (TICH-NOAC): A Multicenter, Randomized, Placebo-Controlled, Phase 2 Trial","volume":"54","author":"Polymeris","year":"2023","journal-title":"Stroke"},{"key":"10.1016\/j.accpm.2025.101584_bib0135","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1177\/2396987319849763","article-title":"European Stroke Organisation Guideline on Reversal of Oral Anticoagulants in Acute Intracerebral Haemorrhage","volume":"4","author":"Christensen","year":"2019","journal-title":"Eur Stroke J"},{"key":"10.1016\/j.accpm.2025.101584_bib0140","article-title":"Tranexamic acid for patients with nasal haemorrhage (epistaxis)","volume":"2018","author":"Joseph","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.accpm.2025.101584_bib0145","article-title":"Antifibrinolytic therapy for preventing oral bleeding in people on anticoagulants undergoing minor oral surgery or dental extractions","volume":"2018","author":"Engelen","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.accpm.2025.101584_bib0150","article-title":"Interventions for heavy menstrual bleeding; overview of Cochrane reviews and network meta-analysis","volume":"2023","author":"Bofill Rodriguez","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.accpm.2025.101584_bib0155","article-title":"Non-surgical interventions for treating heavy menstrual bleeding (menorrhagia) in women with bleeding disorders","volume":"2016","author":"Ray","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.accpm.2025.101584_bib0160","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1182\/blood-2016-01-692053","article-title":"Less menorrhagia for women with VTE","volume":"127","author":"Schulman","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.accpm.2025.101584_bib0165","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1182\/hematology.2020000138","article-title":"Management of heavy menstrual bleeding on anticoagulation","volume":"2020","author":"Samuelson Bannow","year":"2020","journal-title":"Hematology"},{"key":"10.1016\/j.accpm.2025.101584_bib0170","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/rth2.12471","article-title":"Heavy menstrual bleeding on direct factor Xa inhibitors: rationale and design of the MEDEA study","volume":"5","author":"Hamuly\u00e1k","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.accpm.2025.101584_bib0175","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1161\/CIRCULATIONAHA.113.002283","article-title":"Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study","volume":"128","author":"Sarode","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.accpm.2025.101584_bib0180","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.ajem.2014.02.016","article-title":"Use and effectiveness of prothrombin complex concentrates vs fresh frozen plasma in gastrointestinal hemorrhage due to warfarin usage in the ED","volume":"32","author":"Karaca","year":"2014","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.accpm.2025.101584_bib0185","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/S1474-4422(16)00110-1","article-title":"Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial","volume":"15","author":"Steiner","year":"2016","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.accpm.2025.101584_bib0190","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1309\/NQXHUG7HND78LFFK","article-title":"Toward rational fresh frozen plasma transfusion: the effect of plasma transfusion on coagulation test results","volume":"126","author":"Holland","year":"2006","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.accpm.2025.101584_bib0195","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/phar.2261","article-title":"Fixed-dose four-factor prothrombin complex concentrate for vitamin k antagonist reversal: does one dose fit all?","volume":"39","author":"Schwebach","year":"2019","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.accpm.2025.101584_bib0200","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1001\/jama.2015.0846","article-title":"Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage","volume":"313","author":"Kuramatsu","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.accpm.2025.101584_bib0205","article-title":"Pharmacokinetics of Phenprocoumon in Emergency Situations-Results of the Prospective Observational RADOA-Registry (Reversal Agent Use in Patients Treated with Direct Oral Anticoagulants or Vitamin K Antagonists Registry)","volume":"15","author":"Lindhoff-Last","year":"2022","journal-title":"Pharm Basel Switz"},{"key":"10.1016\/j.accpm.2025.101584_bib0210","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1046\/j.1365-2141.2001.03070.x","article-title":"A comparison of the efficacy and rate of response to oral and intravenous Vitamin K in reversal of over-anticoagulation with warfarin","volume":"115","author":"Watson","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.accpm.2025.101584_bib0215","first-page":"5","article-title":"Characterizing the severe reactions of parenteral Vitamin K1","volume":"24","author":"Britt","year":"2018","journal-title":"Clin Appl Thromb Off J Int Acad Clin Appl Thromb"},{"key":"10.1016\/j.accpm.2025.101584_bib0220","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1056\/NEJMoa1707278","article-title":"Idarucizumab for Dabigatran Reversal \u2014 Full Cohort Analysis","volume":"377","author":"Pollack","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.accpm.2025.101584_bib0225","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2020.599626","article-title":"Dabigatran level before reversal can predict hemostatic effectiveness of idarucizumab in a real-world setting","volume":"7","author":"Gendron","year":"2020","journal-title":"Front Med"},{"key":"10.1016\/j.accpm.2025.101584_bib0230","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1111\/jth.14476","article-title":"Pharmacokinetics of idarucizumab and its target dabigatran in patients requiring urgent reversal of the anticoagulant effect of dabigatran","volume":"17","author":"Glund","year":"2019","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.accpm.2025.101584_bib0235","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1177\/1076029618755947","article-title":"The renal elimination pathways of the dabigatran reversal agent idarucizumab and its impact on dabigatran elimination","volume":"24","author":"Glund","year":"2018","journal-title":"Clin Appl Thromb"},{"key":"10.1016\/j.accpm.2025.101584_bib0240","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.bja.2018.04.025","article-title":"Ongoing redistribution of dabigatran necessitates repetitive application of idarucizumab","volume":"121","author":"Hegemann","year":"2018","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.accpm.2025.101584_bib0245","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1016\/j.jacc.2021.04.061","article-title":"Meta-analysis of reversal agents for severe bleeding associated with direct oral anticoagulants","volume":"77","author":"G\u00f3mez-Outes","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.accpm.2025.101584_bib0250","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s11739-020-02433-w","article-title":"Follow-up management of patients receiving direct oral anticoagulants","volume":"16","author":"Fantoni","year":"2021","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.accpm.2025.101584_bib0255","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s11239-016-1410-z","article-title":"Direct oral anticoagulant use and the incidence of bleeding in the very elderly with atrial fibrillation","volume":"42","author":"Khan","year":"2016","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.accpm.2025.101584_bib0260","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1055\/s-0037-1613679","article-title":"Apixaban-calibrated anti-fxa activity in relation to outcome events and clinical characteristics in patients with atrial fibrillation: results from the AVERROES trial","volume":"01","author":"Bhagirath","year":"2017","journal-title":"TH Open"},{"key":"10.1016\/j.accpm.2025.101584_bib0265","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1253\/circj.CJ-18-1282","article-title":"Rivaroxaban or Apixaban for Non-Valvular Atrial Fibrillation \u2015 Efficacy and Safety of Off-Label Under-Dosing According to Plasma Concentration \u2015","volume":"83","author":"Suwa","year":"2019","journal-title":"Circ J"},{"key":"10.1016\/j.accpm.2025.101584_bib0270","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1161\/CIRCULATIONAHA.121.057844","article-title":"Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors","volume":"147","author":"Milling","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.accpm.2025.101584_bib0275","doi-asserted-by":"crossref","DOI":"10.1001\/jamainternmed.2019.2431","article-title":"Perioperative management of patients with atrial fibrillation receiving a direct oral anticoagulant","volume":"179","author":"Douketis","year":"2019","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.accpm.2025.101584_bib0280","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/trf.15560","article-title":"Impact of rivaroxaban plasma concentration on perioperative red blood cell loss","volume":"60","author":"Kaserer","year":"2020","journal-title":"Transfusion (Paris)"},{"key":"10.1016\/j.accpm.2025.101584_bib0285","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1161\/CIRCULATIONAHA.114.013445","article-title":"Edoxaban Effects on Bleeding Following Punch Biopsy and Reversal by a 4-Factor Prothrombin Complex Concentrate","volume":"131","author":"Zahir","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.accpm.2025.101584_bib0290","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1182\/blood-2017-05-782060","article-title":"Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study","volume":"130","author":"Majeed","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.accpm.2025.101584_bib0295","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1055\/s-0038-1636541","article-title":"Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study","volume":"118","author":"Schulman","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.accpm.2025.101584_bib0300","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/jth.13894","article-title":"Rivaroxaban reversal with prothrombin complex concentrate or tranexamic acid in healthy volunteers","volume":"16","author":"Levy","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.accpm.2025.101584_bib0305","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.thromres.2023.01.022","article-title":"Thrombin generation in real life bleeding patients on oral anticoagulants reversed (or not) with (activated) prothrombin complex concentrate","volume":"223","author":"Teissandier","year":"2023","journal-title":"Thromb Res"},{"key":"10.1016\/j.accpm.2025.101584_bib0310","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/ALN.0000000000001631","article-title":"Management of severe bleeding in patients treated with direct oral anticoagulants: an observational registry analysis","volume":"127","author":"Albaladejo","year":"2017","journal-title":"Anesthesiology"},{"key":"10.1016\/j.accpm.2025.101584_bib0315","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1177\/08971900211015059","article-title":"Review of prothrombin complex concentrates use in apixaban and rivaroxaban associated intracranial hemorrhages","volume":"35","author":"Ibarra","year":"2022","journal-title":"J Pharm Pract"},{"key":"10.1016\/j.accpm.2025.101584_bib0320","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.40145","article-title":"Evaluation of direct oral anticoagulant reversal agents in intracranial hemorrhage: a systematic review and meta-analysis","volume":"5","author":"Chaudhary","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.accpm.2025.101584_bib0325","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s12028-015-0222-x","article-title":"Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the neurocritical care society and society of critical care medicine","volume":"24","author":"Frontera","year":"2016","journal-title":"Neurocrit Care"},{"key":"10.1016\/j.accpm.2025.101584_bib0330","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/j.1365-2141.1970.tb00770.x","article-title":"Annotation: heparin therapy and its laboratory control","volume":"18","author":"Pitney","year":"1970","journal-title":"Br J Haematol"},{"key":"10.1016\/j.accpm.2025.101584_bib0335","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1055\/s-0038-1651032","article-title":"The relationship between anti-factor Xa level and clinical outcome in patients receiving enoxaparine low molecular weight heparin to prevent deep vein thrombosis after hip replacement","volume":"62","author":"Levine","year":"1989","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.accpm.2025.101584_bib0340","doi-asserted-by":"crossref","first-page":"e357","DOI":"10.1016\/j.wneu.2021.10.087","article-title":"Supraprophylactic Anti\u2013Factor Xa Levels Are Associated with Major Bleeding in Neurosurgery Patients Receiving Prophylactic Enoxaparin","volume":"157","author":"May","year":"2022","journal-title":"World Neurosurg"},{"key":"10.1016\/j.accpm.2025.101584_bib0345","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1365-2125.2007.02920.x","article-title":"Anti\u2010factor Xa activity of enoxaparin administered at prophylactic dosage to patients over 75 years old","volume":"64","author":"Berges","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.accpm.2025.101584_bib0350","first-page":"237","article-title":"Le suivi biologique des traitements h\u00e9pariniques en 2022: quel(s) examen(s) pr\u00e9f\u00e9rer? Pour quels patients?","volume":"4","author":"Siguret","year":"2022","journal-title":"Rev Fr H\u00e9mostase Thromb"},{"key":"10.1016\/j.accpm.2025.101584_bib0355","doi-asserted-by":"crossref","first-page":"188S","DOI":"10.1378\/chest.126.3_suppl.188S","article-title":"Heparin and Low-Molecular-Weight Heparin","volume":"126","author":"Hirsh","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.accpm.2025.101584_bib0360","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1538-7933.2004.00647.x","article-title":"Is laboratory monitoring of low-molecular-weight heparin therapy necessary? Yes","volume":"2","author":"Harenberg","year":"2004","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.accpm.2025.101584_bib0365","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1055\/s-0038-1645207","article-title":"Neutralization of enoxaparine-induced bleeding by protamine sulfate","volume":"63","author":"Van Ryn-McKenna","year":"1990","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.accpm.2025.101584_bib0370","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1097\/00001721-199410000-00018","article-title":"Protamine neutralization of intravenous and subcutaneous low-molecular-weight heparin (tinzaparin, LogiparinTM). An experimental investigation in healthy volunteers","volume":"5","author":"Holst","year":"1994","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.accpm.2025.101584_bib0375","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1046\/j.1365-2141.2002.03233.x","article-title":"Mechanisms responsible for the failure of protamine to inactivate low\u2010molecular\u2010weight heparin","volume":"116","author":"Crowther","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.accpm.2025.101584_bib0380","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.thromres.2003.09.014","article-title":"Dextran sulfate included in factor Xa assay reagent overestimates heparin activity in patients after heparin reversal by protamine","volume":"111","author":"Mouton","year":"2003","journal-title":"Thromb Res"},{"key":"10.1016\/j.accpm.2025.101584_bib0385","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/MBC.0b013e3283494b3c","article-title":"Protamine reversal of low molecular weight heparin: clinically effective?","volume":"22","author":"Van Veen","year":"2011","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.accpm.2025.101584_bib0390","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0049-3848(02)00031-2","article-title":"Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment","volume":"105","author":"Sanderink","year":"2002","journal-title":"Thromb Res"},{"key":"10.1016\/j.accpm.2025.101584_bib0395","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1136\/rapm-00115550-199823062-00009","article-title":"Statistics: detecting a rare adverse drug reaction using spontaneous reports","volume":"23","author":"Schroeder","year":"1998","journal-title":"Reg Anesth Pain Med"},{"key":"10.1016\/j.accpm.2025.101584_bib0400","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1182\/blood-2016-10-747915","article-title":"Alteration of blood clotting and lung damage by protamine are avoided using the heparin and polyphosphate inhibitor UHRA","volume":"129","author":"Kalathottukaren","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.accpm.2025.101584_bib0405","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.thromres.2008.07.007","article-title":"Reversal of the inhibitory effect of Fondaparinux on Thrombin generation by rFVIIa, aCCP and PCC","volume":"123","author":"Desmurs-Clavel","year":"2009","journal-title":"Thromb Res"},{"key":"10.1016\/j.accpm.2025.101584_bib0410","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1160\/TH10-07-0434","article-title":"Efficacy of prothrombin complex concentrate to reverse the anticoagulant effect of the pentasaccharide fondaparinux in a rabbit model","volume":"105","author":"Godier","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.accpm.2025.101584_bib0415","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1160\/TH07-05-0357","article-title":"Thrombin generation assays are superior to traditional tests in assessing anticoagulation reversal in vitro","volume":"100","author":"Gatt","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.accpm.2025.101584_bib0420","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1160\/TH03-07-0483","article-title":"Recombinant factor VIIa partially reverses the inhibitory effect of fondaparinux on thrombin generation after tissue factor activation in platelet rich plasma and whole blood","volume":"91","author":"Gerotziafas","year":"2004","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.accpm.2025.101584_bib0425","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1161\/01.CIR.0000038501.87442.02","article-title":"Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers","volume":"106","author":"Bijsterveld","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.accpm.2025.101584_bib0430","first-page":"84","article-title":"Chirurgies ou actes invasifs","volume":"20","author":"Godier","year":"2008","journal-title":"Sang Thromb Vaiss"},{"key":"10.1016\/j.accpm.2025.101584_bib0435","first-page":"73","article-title":"Management of direct oral anticoagulants in patients undergoing elective surgeries and invasive procedures: Updated guidelines from the French Working Group on Perioperative Hemostasis (GIHP) \u2013 September 2015","volume":"36","author":"Albaladejo","year":"2017","journal-title":"Anaesth Crit Care Pain Med"},{"key":"10.1016\/j.accpm.2025.101584_bib0440","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jacc.2020.04.053","article-title":"2020 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants","volume":"76","author":"Tomaselli","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.accpm.2025.101584_bib0445","article-title":"Antithrombotic treatment after stroke due to intracerebral haemorrhage","volume":"2023","author":"Cochrane","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.accpm.2025.101584_bib0450","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1001\/jamainternmed.2016.9369","article-title":"Outcomes associated with resuming warfarin treatment after hemorrhagic stroke or traumatic intracranial hemorrhage in patients with atrial fibrillation","volume":"177","author":"Nielsen","year":"2017","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.accpm.2025.101584_bib0455","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1161\/STROKEAHA.110.593087","article-title":"Optimal timing of resumption of warfarin after intracranial hemorrhage","volume":"41","author":"Majeed","year":"2010","journal-title":"Stroke"},{"key":"10.1016\/j.accpm.2025.101584_bib0460","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1161\/STROKEAHA.116.014643","article-title":"Optimal timing of anticoagulant treatment after intracerebral hemorrhage in patients with atrial fibrillation","volume":"48","author":"Pennlert","year":"2017","journal-title":"Stroke"},{"key":"10.1016\/j.accpm.2025.101584_bib0465","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/ajg.2014.398","article-title":"The risks of thromboembolism vs. recurrent gastrointestinal bleeding after interruption of systemic anticoagulation in hospitalized inpatients with gastrointestinal bleeding: a prospective study","volume":"110","author":"Sengupta","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.accpm.2025.101584_bib0470","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.amjcard.2013.10.044","article-title":"Restarting anticoagulation and outcomes after major gastrointestinal bleeding in atrial fibrillation","volume":"113","author":"Qureshi","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.accpm.2025.101584_bib0475","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1093\/eurheartj\/ehy056","article-title":"Management of therapeutic anticoagulation in patients with intracerebral haemorrhage and mechanical heart valves","volume":"39","author":"Kuramatsu","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.accpm.2025.101584_bib0480","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.accpm.2025.101584_bib0485","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/s11739-019-02077-5","article-title":"Vena cava filters in patients presenting with major bleeding during anticoagulation for venous thromboembolism","volume":"14","author":"Mellado","year":"2019","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.accpm.2025.101584_bib0490","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1055\/s-0040-1710589","article-title":"Outcomes after vena cava filter use in patients with cancer-associated venous thromboembolism and contraindications to anticoagulation","volume":"120","author":"Quezada","year":"2020","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.accpm.2025.101584_bib0495","first-page":"S70","article-title":"Prise en charge des surdosages en antivitamines K, des situations \u00e0 risque h\u00e9morragique et des accidents h\u00e9morragiques chez les patients trait\u00e9s par antivitamines K en ville et en milieu hospitalier","volume":"33","author":"Pernod","year":"2008","journal-title":"J Mal Vasc"},{"key":"10.1016\/j.accpm.2025.101584_bib0500","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1001\/archinte.160.11.1612","article-title":"Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation","volume":"160","author":"Hylek","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.accpm.2025.101584_bib0505","doi-asserted-by":"crossref","first-page":"293","DOI":"10.7326\/0003-4819-150-5-200903030-00005","article-title":"Oral Vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: a randomized trial","volume":"150","author":"Crowther","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.accpm.2025.101584_bib0510","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/bjh.14777","article-title":"Assessment of the efficacy of a novel tailored vitamin K dosing regimen in lowering the International Normalised Ratio in over\u2010anticoagulated patients: a randomised clinical trial","volume":"178","author":"Kampouraki","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.accpm.2025.101584_bib0515","first-page":"391","article-title":"Treatment of excessive anticoagulation with phytonadione (Vitamin K): a Meta-analysis","volume":"166","author":"DeZee","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.accpm.2025.101584_bib0520","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S1081-1206(10)62042-X","article-title":"The incidence of anaphylaxis following intravenous phytonadione (vitamin K1): a 5-year retrospective review","volume":"89","author":"Riegert-Johnson","year":"2002","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.accpm.2025.101584_bib0525","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0090199","article-title":"The severe adverse reaction to vitamin K1 injection is anaphylactoid reaction but not anaphylaxis","volume":"9","author":"Mi","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.accpm.2025.101584_bib0530","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.0902-4441.2006.t01-1-EJH2957.x","article-title":"Appraisal of current vitamin K dosing algorithms for the reversal of over\u2010anticoagulation with warfarin: the need for a more tailored dosing regimen","volume":"77","author":"Sconce","year":"2006","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.accpm.2025.101584_bib0535","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/jth.15563","article-title":"Inter\u2010 and intra\u2010individual concentrations of direct oral anticoagulants: The KIDOAC study","volume":"20","author":"Toorop","year":"2022","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.accpm.2025.101584_bib0540","doi-asserted-by":"crossref","first-page":"445","DOI":"10.3390\/biomedicines9050445","article-title":"Laboratory Monitoring of Direct Oral Anticoagulants (DOACs)","volume":"9","author":"Dunois","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.accpm.2025.101584_bib0545","doi-asserted-by":"crossref","first-page":"675","DOI":"10.2165\/11595320-000000000-00000","article-title":"Rivaroxaban: Population Pharmacokinetic Analyses in Patients Treated for Acute Deep-Vein Thrombosis and Exposure Simulations in Patients with Atrial Fibrillation Treated for Stroke Prevention","volume":"50","author":"Mueck","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.accpm.2025.101584_bib0550","first-page":"S24","article-title":"Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban","volume":"29","author":"Gong","year":"2013","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.accpm.2025.101584_bib0555","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jacc.2013.07.104","article-title":"The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients","volume":"63","author":"Reilly","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.accpm.2025.101584_bib0560","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13746","article-title":"Case series of massive direct oral anticoagulant ingestion\u2014Treatment and pharmacokinetics data","volume":"52","author":"Delrue","year":"2022","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.accpm.2025.101584_bib0565","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s40256-013-0055-y","article-title":"Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects","volume":"14","author":"Wang","year":"2014","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.accpm.2025.101584_bib0570","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s40262-016-0485-1","article-title":"Effect of activated charcoal on rivaroxaban complex absorption","volume":"56","author":"Ollier","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.accpm.2025.101584_bib0575","doi-asserted-by":"crossref","first-page":"E122","DOI":"10.1503\/cmaj.211083","article-title":"Management of intentional overdose of low-molecular-weight heparin","volume":"194","author":"Lu","year":"2022","journal-title":"Can Med Assoc J"},{"key":"10.1016\/j.accpm.2025.101584_bib0580","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1182\/blood-2010-06-288522","article-title":"Development of a recombinant antithrombin variant as a potent antidote to fondaparinux and other heparin derivatives","volume":"117","author":"Bianchini","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.accpm.2025.101584_bib0585","first-page":"1779","article-title":"Ponction d\u2019ascite et patient cirrhotique: faut-il craindre les h\u00e9morragies?","volume":"579","author":"De Carvalho Fernandes","year":"2017","journal-title":"Rev Med Suisse"},{"key":"10.1016\/j.accpm.2025.101584_bib0590","first-page":"155","article-title":"Anticoagulants, antiagr\u00e9gants plaquettaires et gestes en rhumatologie","volume":"87","author":"Hugues","year":"2020","journal-title":"Rev Rhum Monogr"},{"key":"10.1016\/j.accpm.2025.101584_bib0595","first-page":"206","article-title":"Anticoagulation and bone marrow biopsy: is it safe to proceed?","volume":"26","author":"Moore","year":"2021","journal-title":"Hematol Amst Neth"},{"issue":"Suppl 1","key":"10.1016\/j.accpm.2025.101584_bib0600","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.1016\/j.rmr.2019.05.009","article-title":"[How to manage anticoagulant treatment in case of invasive procedures (surgery, endoscopy\u2026)]","volume":"38","author":"Godier","year":"2021","journal-title":"Rev Mal Respir"},{"key":"10.1016\/j.accpm.2025.101584_bib0605","unstructured":"Gestion des antiagr\u00e9gants et anticoagulants en endoscopie (Recommandations ESGE). FMC-HGE n.d. https:\/\/www.fmcgastro.org\/texte-postu\/postu-2022\/gestion-des-antiagregants-et-anticoagulants-en-endoscopie-recommandations-esge-2\/ (Accessed 25 June 2025)."},{"key":"10.1016\/j.accpm.2025.101584_bib0610","unstructured":"Endoscopie digestive, anti-Coagulants et anti-agr\u00e9gants: faut-il encore modifier nos pratiques en 2013? FMC-HGE 2013. https:\/\/www.fmcgastro.org\/articles\/endoscopie-digestive-anti-coagulants-et-anti-agregants-faut-il-encore-modifier-nos-pratiques-en-2013\/ (Accessed 25 June 2025)."},{"key":"10.1016\/j.accpm.2025.101584_bib0615","series-title":"Gestion p\u00e9ri-op\u00e9ratoire des patients trait\u00e9s par antithrombotiques en chirurgie","year":"2015"},{"key":"10.1016\/j.accpm.2025.101584_bib0620","unstructured":"Traitements interventionnels de premi\u00e8re intention des calculs urinaires. Haute Aut Sant\u00e9 n.d. https:\/\/www.has-sante.fr\/jcms\/c_2776088\/fr\/traitements-interventionnels-de-premiere-intention-des-calculs-urinaires (Accessed 25 June 2025)."},{"key":"10.1016\/j.accpm.2025.101584_bib0625","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/EJA.0000000000001600","article-title":"Regional anaesthesia in patients on antithrombotic drugs: Joint ESAIC\/ESRA guidelines","volume":"39","author":"Kietaibl","year":"2022","journal-title":"Eur J Anaesthesiol"},{"key":"10.1016\/j.accpm.2025.101584_bib0630","series-title":"Prise en charge des m\u00e9ningites bact\u00e9riennes aigu\u00ebs communautaires","year":"2018"},{"key":"10.1016\/j.accpm.2025.101584_bib0635","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1136\/practneurol-2017-001820","article-title":"Periprocedural antithrombotic management for lumbar puncture: Association of British Neurologists clinical guideline","volume":"18","author":"Dodd","year":"2018","journal-title":"Pract Neurol"},{"key":"10.1016\/j.accpm.2025.101584_bib0640","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1159\/000502735","article-title":"Intracranial hemorrhage following lumbar puncture in a patient on apixaban","volume":"11","author":"Vijapura","year":"2019","journal-title":"Case Rep Neurol"},{"key":"10.1016\/j.accpm.2025.101584_bib0645","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s11910-019-0954-7","article-title":"Patients on NOACs in the emergency room","volume":"19","author":"Gerner","year":"2019","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/j.accpm.2025.101584_bib0650","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.annemergmed.2016.03.003","article-title":"Treatment with prothrombin complex concentrate to enable emergency lumbar puncture in patients receiving vitamin K antagonists","volume":"68","author":"Laible","year":"2016","journal-title":"Ann Emerg Med"},{"key":"10.1016\/j.accpm.2025.101584_bib0655","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s11239-015-1235-1","article-title":"Preoperative INR and postoperative major bleeding and mortality: A retrospective cohort study","volume":"41","author":"Tamim","year":"2016","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.accpm.2025.101584_bib0660","doi-asserted-by":"crossref","first-page":"52","DOI":"10.2106\/JBJS.19.00160","article-title":"Revisiting the International Normalized Ratio Threshold for Bleeding Risk and Mortality in Primary Total Hip Arthroplasty: A National Surgical Quality Improvement Program Analysis of 17,567 Patients","volume":"102","author":"Rudasill","year":"2020","journal-title":"J Bone Joint Surg Am"},{"key":"10.1016\/j.accpm.2025.101584_bib0665","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0049-3848(02)00402-4","article-title":"Correction of INR by prothrombin complex concentrate and vitamin K in patients with warfarin related hemorrhagic complication","volume":"108","author":"Yasaka","year":"2002","journal-title":"Thromb Res"},{"key":"10.1016\/j.accpm.2025.101584_bib0670","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s00134-007-0528-z","article-title":"Ultra-rapid management of oral anticoagulant therapy-related surgical intracranial hemorrhage","volume":"33","author":"Vigu\u00e9","year":"2007","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.accpm.2025.101584_bib0675","doi-asserted-by":"crossref","first-page":"R4","DOI":"10.1186\/cc11923","article-title":"A French multicenter randomised trial comparing two dose-regimens of prothrombin complex concentrates in urgent anticoagulation reversal","volume":"17","author":"Kerebel","year":"2013","journal-title":"Crit Care Lond Engl"},{"key":"10.1016\/j.accpm.2025.101584_bib0680","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1111\/trf.15146","article-title":"Effect of vitamin K administration on rate of warfarin reversal","volume":"59","author":"Polito","year":"2019","journal-title":"Transfusion (Paris)"},{"key":"10.1016\/j.accpm.2025.101584_bib0685","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1345\/aph.1R497","article-title":"Vitamin K dosing to reverse warfarin based on INR, route of administration, and home warfarin dose in the acute\/critical care setting","volume":"46","author":"Tsu","year":"2012","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.accpm.2025.101584_bib0690","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.acvd.2013.04.009","article-title":"Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013","volume":"106","author":"Pernod","year":"2013","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.accpm.2025.101584_bib0695","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.thromres.2022.06.005","article-title":"Management of urgent invasive procedures in patients treated with direct oral Anticoagulants: An observational registry Analysis","volume":"216","author":"Godon","year":"2022","journal-title":"Thromb Res"},{"key":"10.1016\/j.accpm.2025.101584_bib0700","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1093\/eurheartj\/ehx403","article-title":"Predictors of pre-procedural concentrations of direct oral anticoagulants: a prospective multicentre study","volume":"38","author":"Godier","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.accpm.2025.101584_bib0705","first-page":"121","article-title":"Concentrations of direct oral anticoagulants according to guidelines for the periprocedural management of low bleeding risk procedures","volume":"39","author":"Godier","year":"2020","journal-title":"Anaesth Crit Care Pain Med"},{"key":"10.1016\/j.accpm.2025.101584_bib0710","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1182\/bloodadvances.2020002335","article-title":"Predictors of preprocedural direct oral anticoagulant levels in patients having an elective surgery or procedure","volume":"4","author":"Shaw","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.accpm.2025.101584_bib0715","doi-asserted-by":"crossref","first-page":"e226","DOI":"10.3324\/haematol.2017.183400","article-title":"Usefulness of initial plasma dabigatran concentration to predict rebound after reversal","volume":"103","author":"Gendron","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.accpm.2025.101584_bib0720","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1161\/CIRCULATIONAHA.119.041687","article-title":"Specific antidotes for direct oral anticoagulant reversal: case closed or cold case?","volume":"140","author":"Godier","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.accpm.2025.101584_bib0725","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.surg.2016.07.038","article-title":"Should we be following anti-factor Xa levels in patients receiving prophylactic enoxaparin perioperatively?","volume":"161","author":"Pannucci","year":"2017","journal-title":"Surgery"},{"key":"10.1016\/j.accpm.2025.101584_bib0730","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.annfar.2012.10.034","article-title":"Antagonisation des h\u00e9parines et des nouveaux anticoagulants","volume":"32","author":"Kortchinsky","year":"2013","journal-title":"Ann Fr Anesth R\u00e9animation"},{"key":"10.1016\/j.accpm.2025.101584_bib0735","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.anrea.2018.12.002","article-title":"Recommandation sur l\u2019anesth\u00e9sie du sujet \u00e2g\u00e9: l\u2019exemple de fracture de l\u2019extr\u00e9mit\u00e9 sup\u00e9rieure du f\u00e9mur","volume":"5","author":"Aubrun","year":"2019","journal-title":"Anesth R\u00e9animation"},{"key":"10.1016\/j.accpm.2025.101584_bib0740","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s13018-019-1199-5","article-title":"The impact of warfarin on operative delay and 1-year mortality in elderly patients with hip fracture: a retrospective observational study","volume":"14","author":"Caruso","year":"2019","journal-title":"J Orthop Surg"},{"key":"10.1016\/j.accpm.2025.101584_bib0745","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.3390\/jcm9072200","article-title":"Direct oral anticoagulants and timing of hip fracture surgery","volume":"9","author":"Tarrant","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.accpm.2025.101584_bib0750","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s40266-018-0609-4","article-title":"Serum Concentrations and Elimination Rates of Direct-Acting Oral Anticoagulants (DOACs) in Older Hip Fracture Patients Hospitalized for Surgery: A Pilot Study","volume":"36","author":"Viktil","year":"2019","journal-title":"Drugs Aging"},{"key":"10.1016\/j.accpm.2025.101584_bib0755","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s00068-022-02041-7","article-title":"Role of DOAC plasma concentration on perioperative blood loss and transfusion requirements in patients with hip fractures","volume":"49","author":"Hofer","year":"2023","journal-title":"Eur J Trauma Emerg Surg Off Publ Eur Trauma Soc"},{"key":"10.1016\/j.accpm.2025.101584_bib0760","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-020625","article-title":"Should surgery be delayed in patients taking direct oral anticoagulants who suffer a hip fracture? A retrospective, case-controlled observational study at a UK major trauma centre","volume":"8","author":"Mullins","year":"2018","journal-title":"BMJ Open"},{"key":"10.1016\/j.accpm.2025.101584_bib0765","first-page":"E170","article-title":"Safety of expedited-surgery protocols in anticoagulant-treated patients with hip fracture: a systematic review and meta-analysis","volume":"66","author":"You","year":"2023","journal-title":"Can J Surg J Can Chir"},{"key":"10.1016\/j.accpm.2025.101584_bib0770","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.sjpain.2016.11.008","article-title":"Neuraxial blocks and spinal haematoma: Review of 166 case reports published 1994-2015. Part 1: Demographics and risk-factors","volume":"15","author":"Lagerkranser","year":"2017","journal-title":"Scand J Pain"},{"key":"10.1016\/j.accpm.2025.101584_bib0775","unstructured":"Prise en charge des m\u00e9ningites bact\u00e9riennes aigu\u00ebs communautaires (\u00e0 l\u2019exclusion du nouveau-n\u00e9) Actualisation 2017 de La Conf\u00e9rence de Consensus 2008 2017."},{"key":"10.1016\/j.accpm.2025.101584_bib0780","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13741-020-00170-4","article-title":"Markedly increased risk of postoperative bleeding complications during perioperative bridging anticoagulation in general and visceral surgery","volume":"9","author":"Lock","year":"2020","journal-title":"Perioper Med Lond Engl"},{"key":"10.1016\/j.accpm.2025.101584_bib0785","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1538-7836.2011.04572.x","article-title":"Predictors of major bleeding in peri-procedural anticoagulation management","volume":"10","author":"Tafur","year":"2012","journal-title":"J Thromb Haemost JTH"},{"key":"10.1016\/j.accpm.2025.101584_bib0790","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1056\/NEJMoa1501035","article-title":"Perioperative bridging anticoagulation in patients with atrial fibrillation","volume":"373","author":"Douketis","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.accpm.2025.101584_bib0795","article-title":"Postoperative low molecular weight heparin bridging treatment for patients at high risk of arterial thromboembolism (PERIOP2): double blind randomised controlled trial","volume":"373","author":"Kovacs","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.accpm.2025.101584_bib0800","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.rmr.2019.01.003","article-title":"Recommandations de bonne pratique pour la prise en charge de la maladie veineuse thromboembolique chez l\u2019adulte. Version courte","volume":"36","author":"Sanchez","year":"2019","journal-title":"Rev Mal Respir"},{"key":"10.1016\/j.accpm.2025.101584_bib0805","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.rmr.2019.05.038","article-title":"Recommandations de bonne pratique pour la prise en charge de la maladie veineuse thromboembolique chez l\u2019adulte \u2013 Version longue","volume":"38","author":"Sanchez","year":"2021","journal-title":"Rev Mal Respir"},{"key":"10.1016\/j.accpm.2025.101584_bib0810","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.11079","article-title":"Association of inferior vena cava filter placement with rates of pulmonary embolism in patients with cancer and acute lower extremity deep venous thrombosis","volume":"3","author":"Balabhadra","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.accpm.2025.101584_bib0815","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1378\/chest.06-0631","article-title":"A prospective long-term study of 220 patients with a retrievable vena cava filter for secondary prevention of venous thromboembolism","volume":"131","author":"Mismetti","year":"2007","journal-title":"Chest"},{"key":"10.1016\/j.accpm.2025.101584_bib0820","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1001\/jama.2015.3780","article-title":"Effect of a retrievable inferior vena cava filter plus anticoagulation vs anticoagulation alone on risk of recurrent pulmonary embolism: a randomized clinical trial","volume":"313","author":"Mismetti","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.accpm.2025.101584_bib0825","unstructured":"CFCVE - Coll\u00e8ge Fran\u00e7ais de Chirurgie Vasculaire et Endovasculaire n.d. https:\/\/college-vasculaire.com\/ (Accessed 23 June 2025)."},{"key":"10.1016\/j.accpm.2025.101584_bib0830","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.jvsv.2017.05.017","article-title":"Impact of an inferior vena cava filter retrieval algorithm on filter retrieval rates in a cancer population","volume":"5","author":"Litwin","year":"2017","journal-title":"J Vasc Surg Venous Lymphat Disord"},{"key":"10.1016\/j.accpm.2025.101584_bib0835","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(14)60584-5","article-title":"Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials","volume":"384","author":"Emberson","year":"2014","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.accpm.2025.101584_bib0840","doi-asserted-by":"crossref","first-page":"I","DOI":"10.1177\/2396987321989865","article-title":"European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic Stroke","volume":"6","author":"Berge","year":"2021","journal-title":"Eur Stroke J"},{"key":"10.1016\/j.accpm.2025.101584_bib0845","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/ana.23924","article-title":"Safety of intravenous thrombolysis for ischemic stroke in patients treated with warfarin","volume":"74","author":"Mazya","year":"2013","journal-title":"Ann Neurol"},{"key":"10.1016\/j.accpm.2025.101584_bib0850","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1001\/jama.2012.6756","article-title":"Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator","volume":"307","author":"Xian","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.accpm.2025.101584_bib0855","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1161\/STROKEAHA.118.020890","article-title":"Reversal of vitamin K antagonist therapy before thrombolysis for acute ischemic","volume":"49","author":"Chausson","year":"2018","journal-title":"Stroke. Stroke"},{"key":"10.1016\/j.accpm.2025.101584_bib0860","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1001\/jama.2023.8073","article-title":"Recent vitamin K antagonist use and intracranial hemorrhage after endovascular thrombectomy for acute ischemic stroke","volume":"329","author":"Mac Grory","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.accpm.2025.101584_bib0865","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1177\/1747493016669849","article-title":"Thrombolysis and thrombectomy in patients treated with dabigatran with acute ischemic stroke: Expert opinion","volume":"12","author":"Diener","year":"2017","journal-title":"Int J Stroke Off J Int Stroke Soc"},{"key":"10.1016\/j.accpm.2025.101584_bib0870","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/ene.13582","article-title":"Intravenous thrombolysis for acute ischaemic stroke in patients on direct oral anticoagulants","volume":"25","author":"Touz\u00e9","year":"2018","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.accpm.2025.101584_bib0875","doi-asserted-by":"crossref","first-page":"347","DOI":"10.5853\/jos.2017.00395","article-title":"Intravenous Thrombolysis in patients with stroke taking rivaroxaban using drug specific plasma levels: experience with a standard operation procedure in clinical practice","volume":"19","author":"Seiffge","year":"2017","journal-title":"J Stroke"},{"key":"10.1016\/j.accpm.2025.101584_bib0880","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1161\/STROKEAHA.117.017206","article-title":"Intravenous thrombolysis in acute ischemic stroke patients pretreated with non-vitamin K antagonist oral anticoagulants: an editorial review","volume":"48","author":"Tsivgoulis","year":"2017","journal-title":"Stroke"},{"key":"10.1016\/j.accpm.2025.101584_bib0885","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1177\/1747493018790081","article-title":"Prehospital idarucizumab prior to intravenous thrombolysis in a mobile stroke unit","volume":"14","author":"Zhao","year":"2019","journal-title":"Int J Stroke Off J Int Stroke Soc"},{"key":"10.1016\/j.accpm.2025.101584_bib0890","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1177\/1747493019895654","article-title":"Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany-Updated series of 120 cases","volume":"15","author":"Kermer","year":"2020","journal-title":"Int J Stroke Off J Int Stroke Soc"},{"key":"10.1016\/j.accpm.2025.101584_bib0895","doi-asserted-by":"crossref","first-page":"e1968","DOI":"10.1212\/WNL.0000000000009155","article-title":"Stroke reperfusion therapy following dabigatran reversal with idarucizumab in a national cohort","volume":"94","author":"Barber","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.accpm.2025.101584_bib0900","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1159\/000334662","article-title":"Safety and outcomes following thrombolytic treatment in stroke patients who had received prior treatment with anticoagulants","volume":"33","author":"Matute","year":"2012","journal-title":"Cerebrovasc Dis Basel Switz"},{"key":"10.1016\/j.accpm.2025.101584_bib0905","doi-asserted-by":"crossref","DOI":"10.1016\/j.clineuro.2020.106382","article-title":"Intravenous thrombolysis for the management of acute ischemic stroke in patients therapeutically anticoagulated with heparin: a review","volume":"200","author":"Neves","year":"2021","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.accpm.2025.101584_bib0910","doi-asserted-by":"crossref","DOI":"10.1177\/17562864221149249","article-title":"Intravenous thrombolysis in acute ischemic stroke after antagonization of unfractionated heparin with protamine: case series and systematic review of literature","volume":"16","author":"Kneer","year":"2023","journal-title":"Ther Adv Neurol Disord"}],"container-title":["Anaesthesia Critical Care & Pain Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S235255682500116X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S235255682500116X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T17:57:54Z","timestamp":1760551074000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S235255682500116X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":182,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S235255682500116X"],"URL":"https:\/\/doi.org\/10.1016\/j.accpm.2025.101584","relation":{},"ISSN":["2352-5568"],"issn-type":[{"value":"2352-5568","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anticoagulant management in Emergency settings: 2024 guidelines from the French Society of Emergency Medicine (SFMU), the French Society of Anaesthesia and Intensive Care Medicine (SFAR), the French Society of Thrombosis and Haemostasis (SFTH) and the French Working Group on Perioperative Haemostasis (GIHP), endorsed by the French Neurovascular Society","name":"articletitle","label":"Article Title"},{"value":"Anaesthesia Critical Care & Pain Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.accpm.2025.101584","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 Fran\u00e7aise d'Anesth\u00e9sie et de R\u00e9animation (SFAR).","name":"copyright","label":"Copyright"}],"article-number":"101584"}}